Alcon’s Net Sales Grow 8 Percent in Q4-2017, 4 Percent for Full Year

February 2, 2018: By Jon Swedien

Alcon’s net sales for Q4-2017 were $1.56 billion (8 percent, 6 percent cc), parent company Novartis reported Jan. 24.

Alcon’s net sales for the full year were $6 billion (4 percent, 4 percent cc), Novartis reported.

Annual surgical sales were $3.7 billion, up 5 percent (cc), Novartis said in its 2017 annual report. The growth was mainly due to strong performance of products in the vitreoretinal portfolio and growth in cataract disposable surgical supplies, Novartis said.

Vision Care sales were $2.4 billion (3 percent, cc), Novartis said.

CEO Vasant Narasimhan said Novartis is still considering a possible spinoff of Alcon in the first half of 2019. Narasimhan took over for former CEO Joseph Jimenez on Feb. 1.

“We are making progress toward the capital market exit with dedicated teams working toward that,” Narasimhan said in a Jan. 24 earnings call. “But there is no change on the timing of a potential action; we continue to guide toward the potential action in the first half of 2019.”

Novartis posted $12.9 billion (5 percent, 2 percent cc) in Q4-2017. The company’s net sales for the full year were $49 billion (1 percent, 2 percent cc).

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Grants De Novo Request for IDx-DR’s AI Diagnostic System for Diabetic Retinopathy

Allergan Launches TrueTear Intranasal Neurostimulation Device for Dry Eye

Novartis Acquires AveXis, Gene Therapy Platform for $8.7 Billion

Samsung, Biogen Reach Deal with AbbVie over Humira Biosimilar

EyePoint Secures Two US Patents for DEXYCU

SightLife Surgical Rebrands as CorneaGen, Offers New Products

Omidria Earns Listing on VA Formulary, Regains CMS Pass-Through Status

Rayner Launching 600C Monofocal Aspheric IOL in US

LENSAR Laser System Receives 510(k) Clearance for Corneal Pockets, Flaps

EyeGate Completes Enrollment, Receives Milestone Payment for Phase III Study of EGP-437 in Anterior Uveitis

SAV-IOL Seeks $20M in Financing for Active Intraocular Lens Concept with Real-Time Autofocus

AGTC Completes Enrollment for Phase I/II Study of Gene Therapy for X-linked Retinoschisis

Robert Greenberg, MD, PhD, Resigns from Second Sight

US FDA Requires RegeneRx to Conduct Third Phase III Trial for Dry Eye Candidate RGN-259

Stem Cell Implant Yields Positive Results in Phase I/II Study in Dry AMD

Drug Companies Petition Supreme Court to Hear Case Challenging Eye Drop Size

Appeals Court Rules in Favor of Alcon in Suit Brought by Elenza over EAIOLs

ThromboGenics’ THR-137 Demonstrates Safety, Tolerability in Phase I/II Study in DME

GenSight Biologics’ LHON Candidate Improves Eyesight, Fails to Outpace Sham in Phase III Trial

I-MED Pharma’s I-PEN Receives Regulatory Approval in Colombia, Argentina

Coming soon

2018 China Ophthalmic Market Report: An Analysis for 2017 to 2023